|
1
|
Garcia-Aguilar J, Smith DD, Avila K,
Bergsland EK, Chu P and Krieg RM: Timing of Rectal Cancer Response
to Chemoradiation Consortium: Optimal timing of surgery after
chemoradiation for advanced rectal cancer: Preliminary results of a
multicenter, nonrandomized phase II prospective trial. Ann Surg.
254:97–102. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Van Gijn W, Marijnen CA, Nagtegaal ID,
Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius
B and van de Velde CJ: Dutch Colorectal Cancer Group: Preoperative
radiotherapy combined with total mesorectal excision for resectable
rectal cancer: 12-year follow-up of the multicentre, randomised
controlled TME trial. Lancet. 12:575–582. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sauer R, Becker H, Hohenberger W, Rödel C,
Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF,
et al: Preoperative versus postoperative chemoradiotherapy for
rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bosset JF, Collette L, Calais G, Mineur L,
Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A and Ollier
JC: EORTC Radiotherapy Group Trial 22921: Chemotherapy with
preoperative radiotherapy in rectal cancer. N Engl J Med.
355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Martling A, Holm T, Johansson H, Rutqvist
LE and Cedermark B: Stockholm Colorectal Cancer Study Group: The
Stockholm II trial on preoperative radiotherapy in rectal
carcinoma: Long-term follow-up of a population-based study. Cancer.
92:896–902. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bosset JF, Calais G, Mineur L, Maingon P,
Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC,
Bolla M, et al: Fluorouracil-based adjuvant chemotherapy after
preoperative chemoradiotherapy in rectal cancer: Long-term results
of the EORTC 22921 randomised study. Lancet Oncol. 15:184–190.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gérard JP, Conroy T, Bonnetain F, Bouché
O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E,
Maurel J, et al: Preoperative radiotherapy with or without
concurrent fluorouracil and leucovorin in T3-4 rectal cancers:
Results of FFCD 9203. J Clin Oncol. 24:4620–4625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sebag-Montefiore D, Stephens RJ, Steele R,
Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint
AS, et al: Preoperative radiotherapy versus selective postoperative
chemoradiotherapy in patients with rectal cancer (MRC CR07 and
NCIC-CTG C016): A multicenter, randomised trial. Lancet.
373:811–820. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aschele C, Cionini L, Lonardi S, Pinto C,
Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti
P, et al: Primary tumor response to preoperative chemoradiation
with or without oxaliplatin in locally advanced rectal cancer:
Pathologic results of the STAR-01 randomized phase III trial. J
Clin Oncol. 29:2773–2780. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Murata A, Yoshida K, Maeda K, et al: A
randomized phase III trial comparing S-1 versus UFT as adjuvant
chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
ASCO abstract. #3515:2015.
|
|
11
|
Nakamura T, Yamashita K, Sato T, Ema A,
Naito M and Watanabe M: Neoadjuvant chemoradiation therapy using
concurrent S-1 and irinotecan in rectal cancer: Impact on long-term
clinical outcomes and prognostic factors. Int J Radiat Oncol Biol
Phys. 89:547–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Inomata M, Akagi T, Nakajima K, Etoh T,
Shiraishi N, Tahara K, Matsumoto T, Kinoshita T, Fujii K, Shiromizu
A, et al: A prospective feasibility study to evaluate
neoadjuvant-synchronous S-1 with radiotherapy for locally advanced
rectal cancer: A multicentre phase II trial. Mol Clin Oncol.
4:510–514. 2016.
|
|
13
|
Garcia-Aguilar J, Chen Z, Smith DD, Li W,
Madoff RD, Cataldo P, Marcet J and Pastor C: Identification of a
biomarker profile associated with resistance to neoadjuvant
chemoradiation therapy in rectal cancer. Ann Surg. 254:486–493;
discussion 492–493. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Watanabe T, Kobunai T, Yamamoto Y, Matsuda
K, Ishihara S, Nozawa K, Iinuma H, Konishi T, Horie H, Ikeuchi H,
et al: Gene expression signature and response to the use of
leucovorin, fluorouracil and oxaliplatin in colorectal cancer
patients. Clin Transl Oncol. 13:419–425. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nishioka M, Shimada M, Kurita N, Iwata T,
Morimoto S, Yoshikawa K, Higashijima J and Miyatani T: Gene
expression profile can predict pathological response to
preoperative chemoradiotherapy in rectal cancer. Cancer Genomics
Proteomics. 8:87–92. 2011.PubMed/NCBI
|
|
16
|
Tada N, Kawai K, Tsuno NH, Ishihara S,
Yamaguchi H, Sunami E, Kitayama J, Oba K and Watanabe T: Prediction
of the preoperative chemoradiotherapy response for rectal cancer by
peripheral blood lymphocyte subsets. World J Surg Oncol. 13:302015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Spitzner M, Emons G, Kramer F, Gaedcke J,
Rave-Fränk M, Scharf JG, Burfeind P, Becker H, Beissbarth T,
Ghadimi BM, et al: A gene expression signature for
chemoradiosensitivity of colorectal cancer cells. Int J Radiat
Oncol Biol Phys. 78:1184–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours (7th). Wiley-Blackwell.
Hoboken: 2009.
|
|
19
|
Japanese Society for Cancer of the Colon
and Rectum: Japanese Classification of Colorectal Carcinoma (2nd
English). Kanehara Shuppan Co. Ltd. Japan: 2009.
|
|
20
|
Quackenbush J: Microarray data
normalization and transformation. Nat Genet. 32(Suppl): 496–501.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brazma A, Hingamp P, Quackenbush J,
Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA,
Causton HC, et al: Minimum information about a microarray
experiment (MIAME)-toward standards for microarray data. Nat Genet.
29:365–371. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
da Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
da Huang W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: Paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rousseeuw PJ: Silhouettes: A graphical aid
to the interpretation and validation of cluster analysis. Comput
Appl Math. 20:53–65. 1987. View Article : Google Scholar
|
|
25
|
Nishino S, Itoh A, Matsuoka H, Maeda K and
Kamoshida S: Immunohistochemical analysis of organic anion
transporter 2 and reduced folate carrier 1 in colorectal cancer:
Significance as a predictor of response to oral uracil/ftorafur
plus leucovorin chemotherapy. Mol Clin Oncol. 1:661–667.
2013.PubMed/NCBI
|
|
26
|
Pal S, Gupta R and Davuluri RV:
Alternative transcription and alternative splicing in cancer.
Pharmacol Ther. 136:283–294. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haley J and White FM: Adaptive protein and
phosphoprotein networks which promote therapeutic sensitivity or
acquired resistance. Biochem Soc Trans. 42:758–764. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cutillas PR: Role of phosphoproteomics in
the development of personalized cancer therapies. Proteomics Clin
Appl. 9:383–395. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mostowy S and Cossart P: Septins: The
fourth component of the cytoskeleton. Nat Rev Mol Cell Biol.
13:183–194. 2012.PubMed/NCBI
|
|
30
|
Connolly D, Abdesselam I, Verdier-Pinard P
and Montagna C: Septin roles in tumorigenesis. Biol Chem.
392:725–738. 2011. View Article : Google Scholar : PubMed/NCBI
|
